Liposomal Bupivacaine Versus Bupivacaine for for Postoperative Pain Control in Shoulder Surgery

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, single blinded clinical trial whose purpose is to assess the impact of liposomal bupivacaine (LB) in a single shot interscalene nerve block compared with standard bupivacaine (same dose) in a single shot interscalene nerve block in terms of postoperative pain control. Specifically, outpatient pain scores,use of postoperative pain medicine and patient-reported functional outcomes after shoulder arthroplasty surgery will be evaluated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bassett Healthcare
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• patients aged 18 years or older

• undergoing shoulder arthroscopy or arthroplasty

• must meet the criteria for standard of care of ambulatory surgery patients per anesthesia guidelines issued by the American Society of Anesthesiologists

Exclusion criteria:

• contraindications to regional anesthesia,

• allergy to any component of multimodal analgesia

• history of opioid use of >50 morphine milligram equivalents (MME) daily,

• significant peripheral neuropathy or neurologic disorder affecting the upper extremity,

• cognitive or psychiatric condition that might affect the patient?s assessment or inability to provide informed consent

• pregnancy (this is an exclusion for surgery as well)